- Home
- FGEN vs FBRX Comparison
FGEN vs FBRX Comparison
Compare FGEN & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- FBRX
- Stock Information
- Founded
- FGEN 1993
- FBRX N/A
- Country
- FGEN United States
- FBRX United States
- Employees
- FGEN N/A
- FBRX N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- FBRX Health Care
- Exchange
- FGEN Nasdaq
- FBRX Nasdaq
- Market Cap
- FGEN 33.5M
- FBRX 35.3M
- IPO Year
- FGEN 2014
- FBRX N/A
- Fundamental
- Price
- FGEN $0.30
- FBRX $7.32
- Analyst Decision
- FGEN Strong Buy
- FBRX Strong Buy
- Analyst Count
- FGEN 1
- FBRX 4
- Target Price
- FGEN $10.00
- FBRX $77.58
- AVG Volume (30 Days)
- FGEN 1.6M
- FBRX 54.4K
- Earning Date
- FGEN 05-05-2025
- FBRX 03-31-2025
- Dividend Yield
- FGEN N/A
- FBRX N/A
- EPS Growth
- FGEN N/A
- FBRX N/A
- EPS
- FGEN N/A
- FBRX N/A
- Revenue
- FGEN $29,621,000.00
- FBRX N/A
- Revenue This Year
- FGEN $544.98
- FBRX N/A
- Revenue Next Year
- FGEN $9.45
- FBRX N/A
- P/E Ratio
- FGEN N/A
- FBRX N/A
- Revenue Growth
- FGEN N/A
- FBRX N/A
- 52 Week Low
- FGEN $0.18
- FBRX $4.11
- 52 Week High
- FGEN $2.33
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- FGEN 38.86
- FBRX 46.88
- Support Level
- FGEN $0.30
- FBRX $7.10
- Resistance Level
- FGEN $0.38
- FBRX $9.04
- Average True Range (ATR)
- FGEN 0.05
- FBRX 1.27
- MACD
- FGEN -0.00
- FBRX 0.42
- Stochastic Oscillator
- FGEN 16.30
- FBRX 59.82
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).